Oncogene - Table of Contents alert Volume 31 Issue 46

TABLE OF CONTENTS Volume 31, Issue 46 (November 2012) In this issue Review Original Articles Corrigendum Also new AOP Advertisement Cancer Genome Summit 4-6 Dec '12 | Boston Gain exclusive information and expert insights from all cancer genome stakeholders in order to optimize drug development, further personalized medicine and improve patient outcomes This meeting will show you how to identify new drug targets, combat resistance mechanisms, streamline clinical trials and improve clinical management www.cancergenome-summit.com Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Take a look at this recent article in The EMBO Journal:  A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors EMBO open Carolina Vicente-Dueñas et al. The EMBO Journal ¦ doi:10.1038/emboj.2012.227    Review Top Genetic insight and therapeutic targets in squamous-cell lung cancer M L Sos and R K Thomas Oncogene 2012 31: 4811-4814; advance online publication, January 23, 2012; 10.1038/onc.2011.640 Abstract | Full Text Original Articles Top Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16INK4a during immortalization Open C-Y Kan, V W Wen, E Pasquier, K Jankowski, M Chang, L A Richards, M Kavallaris and K L MacKenzie Oncogene 2012 31: 4815-4827; advance online publication, February 6, 2012; 10.1038/onc.2011.645 Abstract | Full Text Intersectin 1 is required for neuroblastoma tumorigenesis A Russo and J P O'Bryan Oncogene 2012 31: 4828-4834; advance online publication, January 23, 2012; 10.1038/onc.2011.643 Abstract | Full Text Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival S Sadagopan, M V Veettil, S Chakraborty, N Sharma-Walia, N Paudel, V Bottero and B Chandran Oncogene 2012 31: 4835-4847; advance online publication, January 23, 2012; 10.1038/onc.2011.648 Abstract | Full Text Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth C Dudgeon, R Peng, P Wang, A Sebastiani, J Yu and L Zhang Oncogene 2012 31: 4848-4858; advance online publication, January 30, 2012; 10.1038/onc.2011.644 Abstract | Full Text Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma E L Carpenter, E A Haglund, E M Mace, D Deng, D Martinez, A C Wood, A K Chow, D A Weiser, L T Belcastro, C Winter, S C Bresler, S Asgharzadeh, R C Seeger, H Zhao, R Guo, J G Christensen, J S Orange, B R Pawel, M A Lemmon and Y P Mossé Oncogene 2012 31: 4859-4867; advance online publication, January 23, 2012; 10.1038/onc.2011.647 Abstract | Full Text Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells G Castoria, P Giovannelli, M Lombardi, C De Rosa, T Giraldi, A de Falco, M V Barone, C Abbondanza, A Migliaccio and F Auricchio Oncogene 2012 31: 4868-4877; advance online publication, January 23, 2012; 10.1038/onc.2011.642 Abstract | Full Text The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression F Babbio, C Pistore, L Curti, I Castiglioni, P Kunderfranco, L Brino, P Oudet, R Seiler, G N Thalman, E Roggero, M Sarti, S Pinton, M Mello-Grand, G Chiorino, C V Catapano, G M Carbone and I M Bonapace Oncogene 2012 31: 4878-4887; advance online publication, February 13, 2012; 10.1038/onc.2011.641 Abstract | Full Text Corrigendum Top Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma E L Carpenter, E A Haglund, E M Mace, D Deng, D Martinez, A C Wood, A K Chow, D A Weiser, L T Belcastro, C Winter, S C Bresler, M Vigny, P Mazot, S Asgharzadeh, R C Seeger, H Zhao, R Guo, J G Christensen, J S Orange, B R Pawel, M A Lemmon and Y P Mossé Oncogene 2012 31: 4888; 10.1038/onc.2012.208 Full Text Advertisement Call for papers! Submit your best work in cancer research, including mechanisms of cellular oncogene activation, structure and function of encoded proteins, DNA and RNA tumor viruses and all other aspects of oncogene structure and function. Our online submission process is easy and can assist you in becoming part of this distinguished journal. Visit our Author page to learn about the benefits of publishing in the Journal and for guidelines on how to submit your paper.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.